These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 38487720)
1. Case report: From sequence to solution: tailoring treatment for transformed follicular lymphoma (DLBCL) through next generation sequencing study. Bouroumeau A; Perdikis-Prati S; Lang N Front Oncol; 2024; 14():1308492. PubMed ID: 38487720 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of Immune Checkpoint Blockade and Biomarkers of Response in Lymphoma: A Narrative Review. Perdikis-Prati S; Sheikh S; Bouroumeau A; Lang N Biomedicines; 2023 Jun; 11(6):. PubMed ID: 37371815 [TBL] [Abstract][Full Text] [Related]
3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
4. Occurrence of Secondary Non-Hodgkin Lymphomas Among Our Classical Hodgkin Lymphoma Patients: A Single-Centre Experience. Virga B; Pinczés L; Illés Á; Miltényi Z; Magyari F; Méhes G; Simon Z Cureus; 2024 Jun; 16(6):e63307. PubMed ID: 39070524 [TBL] [Abstract][Full Text] [Related]
5. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas. Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185 [TBL] [Abstract][Full Text] [Related]
6. PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma. Tobin JWD; Bednarska K; Campbell A; Keane C Cells; 2021 May; 10(5):. PubMed ID: 34068762 [TBL] [Abstract][Full Text] [Related]
7. Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies. Yang RK; Qing Y; Jelloul FZ; Routbort MJ; Wang P; Shaw K; Zhang J; Lee J; Medeiros LJ; Kopetz S; Tetzlaff MT; Broaddus RR Oncotarget; 2020 Feb; 11(6):600-618. PubMed ID: 32110280 [TBL] [Abstract][Full Text] [Related]
9. Predicting Responses to Checkpoint Inhibitors in Lymphoma: Are We Up to the Standards of Solid Tumors? Jeong AR; Ball ED; Goodman AM Clin Med Insights Oncol; 2020; 14():1179554920976366. PubMed ID: 33447123 [TBL] [Abstract][Full Text] [Related]
10. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553 [TBL] [Abstract][Full Text] [Related]
11. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer. Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698 [TBL] [Abstract][Full Text] [Related]
13. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
14. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Chan TA; Yarchoan M; Jaffee E; Swanton C; Quezada SA; Stenzinger A; Peters S Ann Oncol; 2019 Jan; 30(1):44-56. PubMed ID: 30395155 [TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives. Lin N; Song Y; Zhu J Chin J Cancer Res; 2020 Jun; 32(3):303-318. PubMed ID: 32694896 [TBL] [Abstract][Full Text] [Related]
16. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Xu-Monette ZY; Zhou J; Young KH Blood; 2018 Jan; 131(1):68-83. PubMed ID: 29118007 [TBL] [Abstract][Full Text] [Related]
17. Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas. Katsuya H; Suzumiya J; Kimura S Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001659 [TBL] [Abstract][Full Text] [Related]
18. Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer. Kim J; Kim B; Kang SY; Heo YJ; Park SH; Kim ST; Kang WK; Lee J; Kim KM Front Oncol; 2020; 10():314. PubMed ID: 32232003 [No Abstract] [Full Text] [Related]
19. Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignancies. Jeong AR; Trando AH; Thomas SD; Riviere P; Sakowski PJ; Sokol ES; Goodman AM; Kurzrock R Ther Adv Med Oncol; 2024; 16():17588359241273053. PubMed ID: 39220298 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer. Bai Y; Xie T; Wang Z; Tong S; Zhao X; Zhao F; Cai J; Wei X; Peng Z; Shen L J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35241494 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]